Scarica l'app Stockscreener
310.67
20.88%
53.67
Dopo l'orario di chiusura:
312.00
1.33
+0.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$257.00
Aprire:
$293.03
Volume 24 ore:
3.21M
Relative Volume:
3.85
Capitalizzazione di mercato:
$18.08B
Reddito:
$1.98B
Utile/perdita netta:
$420.90M
Rapporto P/E:
53.20
EPS:
5.84
Flusso di cassa netto:
$218.20M
1 W Prestazione:
+20.88%
1M Prestazione:
+17.36%
6M Prestazione:
+15.92%
1 anno Prestazione:
+75.00%
Intervallo 1D:
$293.03
$312.16
Intervallo di 1 settimana:
$252.88
$312.16
Portata 52W:
$160.19
$312.16
Insulet Corporation Stock (PODD) Company Profile
Nome
Insulet Corporation
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Confronta PODD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
310.67 | 18.08B | 1.98B | 420.90M | 218.20M | 5.84 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corporation Borsa (PODD) Ultime notizie
Insulet (PODD) Sees 20.85% Weekly Surge - GuruFocus
Analysts Turn Bullish on Insulet Stock (PODD) after Strong Q1 Earnings - TipRanks
S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points - MSN
Insulet Corporation (NASDAQ:PODD) Q1 2025 Earnings Call Transcript - Insider Monkey
Insulet (PODD) Sees Price Target Boost Amid Strong Sales Performance | PODD Stock News - GuruFocus
BTIG raises Insulet stock price target to $330, maintains Buy rating - Investing.com Nigeria
Insulet’s Earnings Call Reveals Strong Growth and Expansion - TipRanks
Piper Sandler maintains Overweight rating on Insulet stock By Investing.com - Investing.com Canada
Insulet Seeks $30M In Atty Fees, Costs After Trade Secret Win - Law360
U.S. Indexes Ended Friday Mixed As Insulet Led, Affirm Holdings Lagged - Barron's
New Insulet CEO Ashley McEvoy sets priorities - MedTech Dive
Sector Update: Health Care - marketscreener.com
Canaccord raises Insulet stock target to $331, maintains buy rating - Investing.com
Piper Sandler maintains Overweight rating on Insulet stock - Investing.com
Why Insulet (PODD) Stock Is Trading Up Today - Yahoo Finance
Insulet Stock Soars to Lead S&P 500 Gainers Friday - Yahoo Finance
Tesla, Insulet Surge Among Market Cap Stock Movers on Friday By Investing.com - Investing.com Nigeria
Insulet Q1 beat, Sweetgreen sinks on outlook, Wolfspeed drops - Yahoo Finance
Insulet (PODD) Price Target Raised by Oppenheimer Analyst | PODD Stock News - GuruFocus
Tesla, Insulet Surge Among Market Cap Stock Movers on Friday - Investing.com Australia
Insulet (NasdaqGS:PODD) Announces $125M Buyback, Raises Revenue Guidance For 2025 - Yahoo Finance
Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More - Investopedia
Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad - Benzinga
Trade Desk, Insulet Surge in Friday’s Market Cap Stock Movers By Investing.com - Investing.com Nigeria
Trade Desk, Insulet Surge in Friday’s Market Cap Stock Movers - Investing.com Australia
Insulet Stock Is the Top S&P 500 Performer Today. Here’s Why. - MSN
Insulet Posts Upbeat Earnings, Joins Trade Desk, TransMedics Group, Tesla And Other Big Stocks Moving Higher On FridayDefinitive Healthcare (NASDAQ:DH), AvePoint (NASDAQ:AVPT) - Benzinga
Piper Sandler on Insulet Corporation (PODD): 'Strong Update Across the Board' - StreetInsider
Canaccord raises Insulet stock target to $331, maintains buy rating By Investing.com - Investing.com India
BTIG Boosts Price Target for Insulet (PODD) After Strong Q1 Results | PODD Stock News - GuruFocus
Baird Adjusts Price Target on Insulet to $350 From $325, Maintains Outperform Rating - marketscreener.com
Insulet Corporation Exceeds Q1 CY2025 Revenue ExpectationsNews and Statistics - IndexBox
Insulet Corporation (PODD) PT Raised to $331 at Canaccord Genuity - StreetInsider
Insulet Corporation (PODD) PT Raised to $330 at BTIG - StreetInsider
Earnings call transcript: Insulet beats Q1 2025 forecasts, stock surges By Investing.com - Investing.com Nigeria
Insulet Corp (PODD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - GuruFocus
Insulet Corporation Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Insulet beats Q1 2025 forecasts, stock surges - Investing.com Australia
Insulet requests $30 million in attorneys fees after EOFlow trade secret injunction - MLex
Insulet’s (NASDAQ:PODD) Q1: Strong Sales, Stock Soars - Yahoo Finance
Insulet: Q1 Earnings Snapshot - MySA
Insulet's Strong Profit And Innovation Propel Shares Higher - Finimize
Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Insulet Q4 2024 slides: revenue tops $2.1B, margins expand as Type 2 diabetes push begins - Investing.com
Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Insulet Corp (PODD) Q1 2025 Earnings: Revenue Surges to $569M, Beating Estimates, EPS Falls Short at $0.50 - GuruFocus
Insulet Jumps After Beating Quarterly Forecasts, Raising 2025 Expectations - MSN
Insulet earnings beat by $0.23, revenue topped estimates By Investing.com - Investing.com South Africa
Insulet beats quarterly profit estimates on insulin pump demand - marketscreener.com
Insulet earnings beat by $0.23, revenue topped estimates - Investing.com Canada
Insulet Q1 Earnings Fall, Revenue Rises - marketscreener.com
Insulet Corporation Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):